SYNAIRGEN PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.4 GBX | -8.83% |
|
-0.78% | +7.11% |
| 2023 | FTSE 100 Finishes Slightly Lower After Steady Session | DJ |
| 2023 | Synairgen names Phytome's Joseph Colliver as CFO | AN |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 12.89M 16.06M |
|---|---|---|---|---|---|
| Net income 2023 * | -9M -11.22M | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net Debt 2023 * | 650K 810K | Net Debt 2024 * | 5.5M 6.86M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-1.33
x | P/E ratio 2024 * |
-
| Employees | 34 |
| Yield 2023 * |
93.8% | Yield 2024 * |
109% | Free-Float | 96.91% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -8.83% | ||
| 1 week | -0.78% | ||
| Current month | +25.61% | ||
| 1 month | +20.82% | ||
| 3 months | +9.50% | ||
| 6 months | -9.16% | ||
| Current year | +7.11% |
1 week
6.20
8.00
1 month
4.5010.00
Current year
4.0010.00
1 year
4.0013.98
3 years
4.00223.80
5 years
4.00260.00
10 years
4.00260.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | Nov. 05 |
Marcin Mankowski
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Shaw
CHM | Chairman | 59 | 03-05-31 |
Stephen Holgate
FOU | Founder | 77 | 03-05-31 |
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 6.4 | -8.83% | 863,427 |
| 24-04-23 | 7.02 | +4.00% | 30,505 |
| 24-04-22 | 6.75 | 0.00% | 64,104 |
| 24-04-19 | 6.75 | +2.27% | 316,825 |
| 24-04-18 | 6.6 | +2.33% | 247,694 |
Delayed Quote London S.E., April 24, 2024 at 11:35 am EDT
More quotes
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.064
GBP
Average target price
0.4
GBP
Spread / Average Target
+525.00%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.11% | 16.02M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- SNG Stock
